EPCAM and breast carcinoma: Recently, following the positive detection of multiploid EpCAM+ CTECs in locally advanced breast cancer patients receiving neoadjuvant chemotherapy [101], multiploid and triploid PD-L1+ CTECs were reported to respectively show intrinsic and acquired resistance to the immunotherapeutic agent nivolumab (Opdivo) in NSCLC patients [12].